{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-332752","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2026-08-04T20:04:46+00:00","discovered_at":"2026-08-04T20:06:00.692426+00:00","generated_at":"2026-08-04T20:06:53.198856+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences Q2 net loss $45.6M; cash $353.9M; initial Ph2 data from SURF302 expected Sept 2026","bullets":["Net loss of $45.6M in Q2 2026 vs $28.1M in Q2 2025; R&D expenses rose to $39.2M from $24.3M.","Cash, cash equivalents and marketable securities of $353.9M as of June 30, 2026; runway into 2H 2028.","Initial Ph2 data from SURF302 (dabogratinib in IR NMIBC) expected September 2026; n>40 enrolled.","Initial Ph2 data from BEACH301 (achondroplasia) safety sentinel cohort including 5th dose level expected end of Q1 2027.","Appointed Jonathan Day as EVP, Clinical Development; amended ATM sales agreement for up to $250M additional shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-332752","json":"https://secwatch.observer/filing/0001193125-26-332752.json","markdown":"https://secwatch.observer/filing/0001193125-26-332752.md","text":"https://secwatch.observer/filing/0001193125-26-332752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/0001193125-26-332752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/tyra-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:06:53.198856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}